Heat expands cohorts in early stage bladder cancer trial

Heat Biologics' (HTBX) Dose Escalation Committee approves the expansion of the first cohort to the full enrollment of nine patients in its Phase 1/2 study of HS-410 (vesigenpumatucel-L) for the treatment of bladder cancer after the first three patients exhibited no serious adverse events. The trial will eventually enroll 93 patients after transurethral resection of bladder tumor (TURBT) and bacillus Calmette-Guerin (BCG).

The Phase 1 portion evaluates the safety of two doses of HS-410 in bladder cancer patients. Phase 2 evaluates the effectiveness of a vaccination with HS-410 in extending the time of disease recurrence compared to placebo.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs